Hoonmo Lee - 03 Aug 2021 Form 3 Insider Report for Indaptus Therapeutics, Inc. (INDP)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: INDP
Reported as of: 03 Aug 2021
Net transaction value: $0
SEC form: 3
Accepted by SEC: 06 Aug 2021, 16:35:47 UTC
Next SEC filing: 06 Aug 2021
Source filing: View source filing
Reporting owner signature: /s/ Diana Douglas, as Attorney-in-Fact for Hoonmo Lee

Filing notes and source

Key filing fact

Hoonmo Lee filed Form 3 for Indaptus Therapeutics, Inc. (INDP) on 06 Aug 2021.

Key facts

This page summarizes Hoonmo Lee's Form 3 filing for Indaptus Therapeutics, Inc. (INDP).
0 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 06 Aug 2021, 16:35.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INDP holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 694,522
Date: 03 Aug 2021
Ownership: see footnote
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Consists of 694,522 shares of common stock held by TY Bio Investment, Inc. Mr. Lee shares investment authority over TY Bio Investment, Inc. Accordingly, Mr. Lee may be deemed to beneficially own the shares of Indaptus Therapeutics, Inc. common stock held by TY Bio Investment.